Gain Therapeutics CEO Alder departs; CFO Mack named interim CEO, Chairman Islam becomes Executive Chairman

Gain Therapeutics, Inc.

CEO Matthias Alder left June 25, 2024 to pursue other opportunities; separation includes 12 months salary, COBRA, accelerated vesting.
CFO Gene Mack appointed interim CEO effective June 25, 2024 and retains CFO role with no additional compensation.
Chairman Khalid Islam, PhD, named Executive Chairman to advise Mack until a permanent CEO is found.
Company's lead candidate GT-02287, an allosteric small molecule for Parkinson's, is in Phase 1 clinical development.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Gene Mack

Interim Chief Executive Officer

GANX · Gain Therapeutics, Inc.

Effective: 2024-06-25
Filed: June 28, 2024, 7:59 PM ET

On June 27, 2024, Mr. Gene Mack (“Mr. Mack”), the Company’s current Chief Financial Officer, was appointed to serve as Interim Chief Executive Officer (“Interim CEO”), effective as June 25, 2024, to fill the vacancy created by Mr. Alder’s departure as Chief Executive Officer.

Departed

Matthias Alder

Chief Executive Officer

GANX · Gain Therapeutics, Inc.

Effective: 2024-06-25
Successor: Gene Mack
Filed: June 28, 2024, 7:59 PM ET

On June 25, 2024, Matthias Alder (“Mr. Alder”), Chief Executive Officer of Gain Therapeutics, Inc. (the “Company”), and the Company mutually agreed that his service as Chief Executive Officer of the Company would terminate so that Mr. Alder can pursue other opportunities.

Appointed

Khalid Islam

Executive Chairman of the Board

GANX · Gain Therapeutics, Inc.

Effective: 2024-06-25
Filed: June 28, 2024, 7:59 PM ET

On June 27, 2024, Dr. Khalid Islam (“Dr. Islam”), the current Chairman of the Board, was appointed to serve as Executive Chairman of the Board, effective June 25, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Gene Mack was appointed as Interim Chief Executive Officer at Gain Therapeutics, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

On June 27, 2024, Mr. Gene Mack (“Mr. Mack”), the Company’s current Chief Financial Officer, was appointed to serve as Interim Chief Executive Officer (“Interim CEO”), effective as June 25, 2024, to fill the vacancy created by Mr. Alder’s departure as Chief Executive Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Matthias Alder was terminated as Chief Executive Officer at Gain Therapeutics, Inc..

Action: terminated
Role: Chief Executive Officer

Exact text from the filing

On June 25, 2024, Matthias Alder (“Mr. Alder”), Chief Executive Officer of Gain Therapeutics, Inc. (the “Company”), and the Company mutually agreed that his service as Chief Executive Officer of the Company would terminate so that Mr. Alder can pursue other opportunities.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Khalid Islam was appointed as Executive Chairman of the Board at Gain Therapeutics, Inc..

Action: appointed
Role: Executive Chairman of the Board

Exact text from the filing

On June 27, 2024, Dr. Khalid Islam (“Dr. Islam”), the current Chairman of the Board, was appointed to serve as Executive Chairman of the Board, effective June 25, 2024.

View on SEC.gov

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-076341

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.